Rezpegaldesleukin Shows Strong Phase 2b Results for Atopic Dermatitis, Asthma | HCPLive Late-breaking REZOLVE-AD data show rezpegaldesleukin 24 μg/kg improves skin and asthma, supporting its potential in moderate-to-severe atopic dermatitis.

Rezpegaldesleukin shows strong phase 2b results, improving both #AtopicDermatitis severity and asthma control, especially in patients with uncontrolled asthma. #ACAAI2025
Read more here:

Atopic Diseases Significantly Raise the Risk of Post-Surgical Complications | HCPLive Two large cohort studies found greater infection and implant-related risks in patients with atopic skin conditions after major surgeries.

Two new studies presented at #ACAAI2025 indicated that atopic conditions may increase the risk of post-surgical issues. Read about the studies here: www.hcplive.com/view... #Dermatology #AtopicDermatitis #Eczema

Eczema Onset at 4 Months May Reduce the Chance of Outgrowing Food Allergies | HCPLive Study finds eczema onset at 4–6 months, greater severity, and longer duration linked to lower odds of outgrowing food allergies in children.

A study presented at #ACAAI2025 reported a link between earlier onset of eczema between 4 to 6 months with a reduced likelihood of outgrowing food allergies. Read more about the findings:

A phase 2b trial presented as a late breaker at #ACAAI2025 demonstrates the effectiveness of rezpegaldesleukin, an IL-2 receptor pathway agonist, for the treatment of atopic dermatitis and asthma. Learn more: www.hcplive.com/view...

Donidalorsen continues to show durable, long-term efficacy for #HAE across OASISplus extension and switch data. Check out interview with Daniel Manning, MD, here: www.hcplive.com/view... #ACAAI2025

New data from the phase 3b ADmirable trial show lebrikizumab effectively treats severe atopic dermatitis in patients with skin of color. Vinay Mehta, MD, breaks down what clinicians need to know at #ACAAI2025: www.hcplive.com/view/lebriki...

Our top trial recaps from #ACAAI2025 are live.
From sublingual epinephrine in kids to new #HES, #CSU, #rhinosinusitis, and pediatric #atopicdermatitis data, we break down 4 late-breakers and phase 3 trials shaping #allergy & #immunology care.
Read the full coverage here: www.hcplive.com/view...

Does the Future of Asthma Treatment Involve Fewer Corticosteroids? Risks are becoming increasingly clear

"Every little bit matters and we really need to tighten the screws to try to minimize it as much as possible." -- Jay Lieberman, MD, of @uthsc.bsky.social, on the shift away from #corticosteroids for #asthma. #ACAAI2025
www.medpagetoday.com/meetingcover...

Kids' Neuropsychiatric Events on Montelukast More Common With Psych History Study shows more than four-fold risk in children who already have psychiatric conditions

"They're going to blame the drug if things go wrong, and so I don't want to go down that path." -- John Oppenheimer, MD, on #neuropsychiatric concerns associated with montelukast (Singulair) for #allergy and #asthma treatment in some children. #ACAAI2025
www.medpagetoday.com/meetingcover...

COVID-19 Vaccination Linked to Reduced Infections in Children with Eczema “We found lower rates of both allergic conditions and infections among vaccinated children compared to their unvaccinated peers.”

An important study presented at #ACAAI2025 showed that vaccinated children with eczema had lower rates of both allergic conditions and infections compared to their unvaccinated peers. Eczema is an early step in the "atopic march" toward #foodallergies.

Will you be in Orlando this week for #ACAAI2025? Be sure to catch Lumanity's co-authored poster presentations at the meeting: buff.ly/TAN0BsX

#ACAAI #ACAAI2025 #Allergy #Asthma #Immunology #HAE #Angioedema #ITC